We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors.
- Authors
Perelman, Moran Gvili; Brzezinski, Rafael Y.; Waissengrin, Barliz; Leshem, Yasmin; Bainhoren, Or; Rubinstein, Tammi Arbel; Perelman, Maxim; Rozenbaum, Zach; Havakuk, Ofer; Topilsky, Yan; Banai, Shmuel; Wolf, Ido; Laufer-Perl, Michal
- Abstract
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective antidiabetic therapies associated with reduced all-cause mortality and cardiovascular (CV) outcomes. Objective: To evaluate the prognostic value of SGLT2i on all-cause mortality and cardiotoxicity among patients treated with ICIs. Methods: We performed a retrospective analysis of patients diagnosed with cancer and type 2 DM (DM2) and treated with ICIs at our center. Patients were divided into two groups according to baseline treatment with or without SGLT2i. The primary endpoint was all-cause mortality and the secondary endpoint was MACE, including myocarditis, acute coronary syndrome, heart failure, and arrhythmia. Results: The cohort included 119 patients, with 24 (20%) patients assigned to the SGLT2i group. Both groups exhibited a comparable prevalence of cardiac risk factors, although the SGLT2i group displayed a higher incidence of ischemic heart disease. Over a median follow-up of 28 months, 61 (51%) patients died, with a significantly lower all-cause mortality rate in the SGLT2i group (21% vs. 59%, p = 0.002). While there were no significant differences in MACE, we observed zero cases of myocarditis and atrial fibrillation in the SGLT2i, compared to 2 and 6 cases in the non-SGLT2i group. Conclusions: SGLT2i therapy was associated with a lower all-cause mortality rate in patients diagnosed with cancer and DM2 and treated with ICIs. Further studies are needed to understand the mechanism and evaluate its benefit on cardiotoxicity.
- Subjects
ISRAEL; GLUCOSE analysis; CAUSES of death; CARDIOTOXICITY; STATISTICS; IMMUNE checkpoint inhibitors; SPECIALTY hospitals; SCIENTIFIC observation; CARDIOMYOPATHIES; MULTIVARIATE analysis; LOG-rank test; RETROSPECTIVE studies; ACUTE coronary syndrome; ACQUISITION of data; MANN Whitney U Test; TYPE 2 diabetes; TREATMENT effectiveness; CANCER patients; CANCER treatment; RISK assessment; COMPARATIVE studies; T-test (Statistics); DISEASE prevalence; CARDIAC arrest; DESCRIPTIVE statistics; MEDICAL records; CHI-squared test; KAPLAN-Meier estimator; SODIUM-glucose cotransporter 2 inhibitors; TUMORS; ARRHYTHMIA; DATA analysis software; LONGITUDINAL method; HEART failure; PROPORTIONAL hazards models; DISEASE risk factors
- Publication
Cardio-Oncology, 2024, Vol 10, Issue 1, p1
- ISSN
2057-3804
- Publication type
Article
- DOI
10.1186/s40959-023-00199-6